Form 483

Sovereign Pharmaceuticals, LLC Form 483, 2025-05-12

FDA issued a Form 483 to Sovereign Pharmaceuticals, LLC on 2025-05-12 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Sovereign Pharmaceuticals, LLC · Fort Worth, United States · Issued May 12, 2025

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 4 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

12 May 2025
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Margaret M Annes, Milton J De Jesus Tavarez, Stephon D Tillis, Jeffrey T Prosterman

12 May 2025
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Margaret M Annes, Milton J De Jesus Tavarez, Stephon D Tillis, Jeffrey T Prosterman

12 May 2025
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Margaret M Annes, Milton J De Jesus Tavarez, Stephon D Tillis, Jeffrey T Prosterman

12 May 2025
21 CFR 211.84(d)(2)

Component written specification

Cited by Margaret M Annes, Milton J De Jesus Tavarez, Stephon D Tillis, Jeffrey T Prosterman

Inspected site

SPSovereign Pharmaceuticals, LLCFort Worth, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 4 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere